Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC5 | P28715 | 2/20 | 0.39 |
| ▸ | FEN1 | P39748 | 2/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 8/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 7/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.35 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.34 |
| ▸ | PGR | P06401 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5642724 | 0.83 | NR3C1 (0.45) | NR3C1NR3C2PGR | |
| SCHEMBL5643364 | 0.82 | NR3C2 (0.38) | ERCC5FEN1NR3C1NR3C2 | |
| SCHEMBL27576203 | 0.79 | IDO1 (0.35) | NR3C1NR3C2 | |
| SCHEMBL3889197 | 0.79 | NR3C2 (0.53) | NR3C1NR3C2PGR | |
| SCHEMBL20535148 | 0.79 | PTGFR (0.43) | NR3C1NR3C2TBXA2RANO1 | |
| SCHEMBL4823384 | 0.78 | FEN1 (0.45) | ERCC5FEN1 | |
| SCHEMBL332047 | 0.74 | ALDH1A1 (0.39) | ERCC5FEN1 | |
| SCHEMBL5643335 | 0.72 | KCNN4 (0.47) | — | |
| SCHEMBL803635 | 0.70 | PTGS1 (0.39) | NR3C1NR3C2PGR | |
| SCHEMBL379397 | 0.70 | NR3C1 (0.47) | NR3C1NR3C2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1659144-B | Quinoline and isoquinoline derivatives, process for their preparation and their use as inflammation inhibitors | SCHERING AG | 2010-09-08 | — | — | CN | disclosed |
| US-7329753-B2 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | SCHERING AG (DE) | 2008-02-12 | — | — | US | disclosed |
| EP-1492771-B1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | SCHERING AG (DE) | 2007-02-28 | — | — | EP | disclosed |
| CN-1915231-A | Use of nonsteroidal in preparing drug of antiinflammatory agents | SCHERING AG (DE) | 2007-02-21 | — | — | CN | disclosed |
| US-7166592-B2 | Antiinflammatory agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-01-23 | — | — | US | disclosed |
| US-7129270-B2 | Nonsteroidal antiinflammatory agents | Schėring AG (DE) | 2006-10-31 | — | — | US | disclosed |
| US-20060229333-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2006-10-12 | — | — | US | disclosed |
| US-7109212-B2 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | SCHERING AG (DE) | 2006-09-19 | — | — | US | disclosed |
| US-20060040933-A1 | Nonsteroidal antiinflammatory agents | JAROCH STEFAN | 2006-02-23 | — | — | US | disclosed |
| CN-1659144-A | Quinoline and isoquinoline derivatives, process for their preparation and their use as inflammation inhibitors | SCHERING AG (DE) | 2005-08-24 | — | — | CN | disclosed |
| US-6897224-B2 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | SCHERING AG (DE) | 2005-05-24 | — | — | US | disclosed |
| EP-1492771-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-01-05 | — | — | EP | disclosed |
| US-20040254249-A1 | Nonsteroidal antiinflammatory agents | JAROCH STEFAN (DE) | 2004-12-16 | — | — | US | disclosed |
| US-6777409-B2 | FOR THERAPY OF INFLAMMATION | SCHERING AKTIENGESELLSCHAFT PATENTS (DE) | 2004-08-17 | — | — | US | disclosed |
| US-20040116694-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | SCHERING AG (DE) | 2004-06-17 | — | — | US | disclosed |
| WO-2003082827-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-10-09 | — | — | WO | disclosed |
| CN-1444570-A | Non-steroidal anti-inflammatory drugs | SCHERING AG (DE) | 2003-09-24 | — | — | CN | disclosed |
| EP-1309571-A1 | NON-STEROIDAL INFLAMMATION INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-14 | — | — | EP | disclosed |
| US-20020077356-A1 | Nonsteroidal antiinflammatory agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-06-20 | — | — | US | disclosed |
| WO-2002010143-A1 | NON-STEROIDAL INFLAMMATION INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077356-A1 | Nonsteroidal antiinflammatory agents | PTGS1, PTGES2, PTGES | ERCC5 4307/4885FEN1 1195/4885NR3C1 98/4885 |
| US-20060040933-A1 | Nonsteroidal antiinflammatory agents | PTGES, PTGES2, PTGS1 | ERCC5 4005/4885FEN1 1587/4885NR3C1 150/4885 |
| US-20060229333-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | NFKBIA, IL1B, IRF3 | ERCC5 3789/4885FEN1 4331/4885NR3C1 2380/4885 |
| US-20040254249-A1 | Nonsteroidal antiinflammatory agents | PTGS1, PTGER1, PTGES2 | ERCC5 4272/4885FEN1 1059/4885NR3C1 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.